Media about us

01 August 2016

Will Liquid Biopsies Transform Oncology Clinical Trials?

Ed Miseta / Clinical Leader

Epic Sciences says it has developed a technology that CEO Murali Prahalad believes will transform oncology trials by identifying and characterizing circulating tumor cells. Those cells have been long recognized as a key part of cancer metastasis. Tumors shed these cells into the circulatory system where they then travel to different parts of the body and, under the right conditions, become the genesis of new tumors.

Pfizer Partners with NovaMedica to Build Manufacturing Unit in Russia

Jerry Boling / Market Digest

Pfizer Inc. (NYSE: PFE) is currently in the process of developing several manufacturing units in a number of geographical territories all over the world. Just recently, the pharmaceutical giant inked its third major deal in the in the past couple of years. This huge deal involves a partnership with NovaMedica of Russia to establish a manufacturing facility in the country.

19 July 2016

Pfizer agrees to license 30 products to Russian pharma company

Life Sciences IP Review

US drugs company Pfizer has entered into a manufacturing and licensing agreement with Russian pharmaceutical company NovaMedica. Pfizer has proposed to invest in NovaMedica’s construction of a new manufacturing plant in the Kaluga region.

19 July 2016

Pfizer, NovaMedica Announce Strategic Partnership in Russia

Drug Discovery & Development

Pfizer, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have announced the start of a long-term strategic partnership to locally manufacture and bring to the Russian market a number of important medicines. The first step will be the construction of a modern pharmaceutical manufacturing plant located in the Vorsino industrial park, Kaluga Region. 

18 July 2016

Pfizer Inc. (PFE) Ready to Reconnoiter Russian Therapeutic Markets

Raheel Farooq / Business Finance News

As restrictions in the Western countries rise and growth remains stagnant, Pfizer has taken a wise step to slowly and steadily enter Russia with the establishment of a manufacturing unit. Pfizer Inc. is in the process to develop manufacturing facilities in numerous geographical territories around the globe. Recently, the drug maker signed its third mega deal in the past several years, which is an agreement with Russia’s NovaMedica to build a manufacturing unit.

18 July 2016

Pfizer strikes second deal this year for drug production in Russia

Eric Palmer / Fierce Pharma

Pfizer was a little behind some of its peers in establishing local manufacturing in Russia but it's on a roll now, having just announced its third deal in several years. It is hammering out an agreement with Russia’s NovaMedica for a new manufacturing plant. 

15 July 2016

Atlas Genetics mandates UBS for up to USD 30m raise — source

Mergermarket

Atlas Genetics (AG), a UK-based, PE-backed point-of-care (POC) diagnostics company, is looking to raise up to USD 30m to fund clinical trials and commercialization, a source familiar with the situation said. The company has developed ultra-rapid, low cost, multiple analyte detection technology for POC use to screen the presence of sexually transmitted infections (STIs) and hospital acquired infections (HAIs).

15 July 2016

Pfizer's Russia Deal Shows Country Still Open To Western Business

Kenneth Rapoza / Forbes

U.S. multinational drug maker Pfizer PFE +1.68% is laying down a new foundation in Russia, with a joint venture announced on Wednesday to produce pharmaceuticals domestically.

15 July 2016

Pfizer links with NovaMedica to produce and market drugs in Russia

The Pharma Letter

US pharma giant Pfizer (NYSE: PFE) and NovaMedica, a company established by Russian high-technology investment fund Rusnano and American venture health care fund Domain Associates in 2012, have entered into an agreement to cooperate, signalling the development of a new partnership, to bring important medicines to the Russian market.

13 July 2016

Photo: Pfizer and NovaMedica announce a strategic partnership in Russia

Pfizer, one of the world’s premier biopharmaceutical companies and NovaMedica, a Russian pharmaceutical company established by Rusnano and Domain Associates, have entered into an agreement to cooperate, signalling the development of a new partnership. Through this partnership, Pfizer proposes to invest in NovaMedica’s construction of a new manufacturing plant in the Kaluga region and license the technology for production of more than 30 medicinal products from its portfolio to the Russian partner.